Dermata Therapeutics, Inc.
DRMA · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $5 | $1 | $1 | $0 |
| - Cash | $5 | $6 | $10 | $3 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $0 | -$6 | -$9 | -$3 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| EBITDA | -$2 | -$2 | -$2 | -$3 |
| % Margin | – | – | – | – |
| Net Income | -$2 | -$2 | -$2 | -$3 |
| % Margin | – | – | – | – |
| EPS Diluted | -1.65 | -1.66 | -4.47 | -20.4 |
| % Growth | 0.6% | 62.9% | 78.1% | – |
| Operating Cash Flow | -$2 | -$3 | -$2 | -$3 |
| Capital Expenditures | -$0 | $0 | -$0 | $0 |
| Free Cash Flow | -$2 | -$3 | -$2 | -$3 |